Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirus

Viruses

Volumn 8, Issue 4, 2016, Pages

  Nie, Jianhui ^a   Liu, Yangyang ^a   Huang, Weijin ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

FluoroSpot; HPV; Human papillomavirus; Multiplex immunoassay; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; PHOTOPROTEIN; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 58; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRION; VIRUS NEUTRALIZATION; WART VIRUS; CELL LINE; CLASSIFICATION; FLUOROIMMUNOASSAY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROCEDURES; REPORTER GENE; REPRODUCIBILITY; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; FLUOROIMMUNOASSAY; GENE EXPRESSION; GENES, REPORTER; HUMANS; LUMINESCENT PROTEINS; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCIBILITY OF RESULTS;

EID: 84964845108     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8040107     Document Type: Article

References (34)

1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87-108. [CrossRef] [PubMed]
2. Bravo, I.G.; Felez-Sanchez, M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol. Med. Public Health 2015, 2015, 32-51. [CrossRef] [PubMed]
3. Armstrong, E.P. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. J. Manag. Care Pharm. 2010, 16, 217-230. [CrossRef] [PubMed]
4. Zhao, H.; Lin, Z.-J.; Huang, S.-J.; Li, J.; Liu, X.-H.; Guo, M.; Zhang, J.; Xia, N.-S.; Pan, H.-R.;Wu, T.; Li, C.G. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum. Vaccines Immunother. 2014, 10, 740-746. [CrossRef]
5. Cassidy, B.; Schlenk, E.A. Uptake of the human papillomavirus vaccine: A review of the literature and report of a quality assurance project. J. Pediatr. Health Care 2012, 26, 92-101. [CrossRef] [PubMed]
6. Joura, E.A.; Giuliano, A.R.; Iversen, O.E.; Bouchard, C.; Mao, C.; Mehlsen, J.; Moreira, E.D., Jr.; Ngan, Y.; Petersen, L.K.; Lazcano-Ponce, E.; et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015, 372, 711-723. [CrossRef] [PubMed]
7. Opalka, D.; Lachman, C.E.; MacMullen, S.A.; Jansen, K.U.; Smith, J.F.; Chirmule, N.; Esser, M.T. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 2003, 10, 108-115. [CrossRef] [PubMed]
8. Scherpenisse, M.; Mollers, M.; Schepp, R.M.; Boot, H.J.; de Melker, H.E.; Meijer, C.J.; Berbers, G.A.; van der Klis, F.R. Seroprevalence of seven high-risk HPV types in the Netherlands. Vaccine 2012, 30, 6686-6693. [CrossRef] [PubMed]
9. Waterboer, T.; Sehr, P.; Michael, K.M.; Franceschi, S.; Nieland, J.D.; Joos, T.O.; Templin, M.F.; Pawlita, M. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin. Chem. 2005, 51, 1845-1853. [CrossRef] [PubMed]
10. Doorbar, J.; Quint, W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30, F55-F70. [CrossRef] [PubMed]
11. Buck, C.B.; Pastrana, D.V.; Lowy, D.R.; Schiller, J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004, 78, 751-757. [CrossRef] [PubMed]
12. Pastrana, D.V.; Buck, C.B.; Pang, Y.Y.; Thompson, C.D.; Castle, P.E.; FitzGerald, P.C.; Kruger Kjaer, S.; Lowy, D.R.; Schiller, J.T. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321, 205-216. [CrossRef] [PubMed]
13. Wu, X.; Zhang, C.; Feng, S.; Liu, C.; Li, Y.; Yang, Y.; Gao, J.; Li, H.; Meng, S.; Li, L.; et al. Detection of HPV types and neutralizing antibodies in Gansu province, China. J. Med. Virol. 2009, 81, 693-702. [CrossRef] [PubMed]
14. Sehr, P.; Rubio, I.; Seitz, H.; Putzker, K.; Ribeiro-Muller, L.; Pawlita, M.; Muller, M. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS ONE 2013, 8, e75677. [CrossRef] [PubMed]
15. Nie, J.; Huang, W.; Wu, X.; Wang, Y. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J. Med. Virol. 2014, 86, 1542-1555. [CrossRef] [PubMed]
16. Panicker, G.; Rajbhandari, I.; Gurbaxani, B.M.; Querec, T.D.; Unger, E.R. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J. Immunol. Methods 2015, 417, 107-114. [CrossRef] [PubMed]
17. Hadjilaou, A.; Green, A.M.; Coloma, J.; Harris, E. Single-cell analysis of B cell/antibody cross-reactivity using a novel multicolor FluoroSpot assay. J. Immunol. 2015, 195, 3490-3496. [CrossRef] [PubMed]
18. Leder, C.; Kleinschmidt, J.A.; Wiethe, C.; Muller, M. Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 2001, 75, 9201-9209. [CrossRef] [PubMed]
19. Pastrana, D.V.; Gambhira, R.; Buck, C.B.; Pang, Y.Y.; Thompson, C.D.; Culp, T.D.; Christensen, N.D.; Lowy, D.R.; Schiller, J.T.; Roden, R.B. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337, 365-372. [CrossRef] [PubMed]
20. Mossadegh, N.; Gissmann, L.; Muller, M.; Zentgraf, H.; Alonso, A.; Tomakidi, P. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004, 326, 57-66. [CrossRef] [PubMed]
21. Kieback, E.; Muller, M. Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. Virology 2006, 345, 199-208. [CrossRef] [PubMed]
22. Kondo, K.; Ishii, Y.; Ochi, H.; Matsumoto, T.; Yoshikawa, H.; Kanda, T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007, 358, 266-272. [CrossRef] [PubMed]
23. Roberts, J.N.; Buck, C.B.; Thompson, C.D.; Kines, R.; Bernardo, M.; Choyke, P.L.; Lowy, D.R.; Schiller, J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13, 857-861. [CrossRef] [PubMed]
24. Kondo, K.; Ochi, H.; Matsumoto, T.; Yoshikawa, H.; Kanda, T. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 2008, 80, 841-846. [CrossRef] [PubMed]
25. Johnson, K.M.; Kines, R.C.; Roberts, J.N.; Lowy, D.R.; Schiller, J.T.; Day, P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 2009, 83, 2067-2074. [CrossRef] [PubMed]
26. Wu, X.L.; Zhang, C.T.; Zhu, X.K.; Wang, Y.C. Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. Virol. Sin. 2010, 25, 8-17. [CrossRef] [PubMed]
27. Buck, C.B.; Thompson, C.D. Production of papillomavirus-based gene transfer vectors. Curr. Protoc. Cell Biol. 2007. [CrossRef]
28. Matumoto, M. A note on some points of calculation method of LD50 by Reed and Muench. Jpn. J. Exp. Med. 1949, 20, 175-179. [PubMed]
29. Ferguson, M.;Wilkinson, D.E.; Heath, A.; Matejtschuk, P. The first international standard for antibodies to HPV 16. Vaccine 2011, 29, 6520-6526. [CrossRef] [PubMed]
30. Stanley, M.; Pinto, L.A.; Trimble, C. Human papillomavirus vaccines-Immune responses. Vaccine 2012, 30, F83-F87. [CrossRef] [PubMed]
31. Ahlborg, N.; Axelsson, B. Dual-and triple-color fluorospot. Methods Mol. Biol. 2012, 792, 77-85. [PubMed]
32. Wheeler, C.M.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.E.; Hernandez-Avila, M.; Perez, G.; Brown, D.R.; Koutsky, L.A.; Tay, E.H.; Garcia, P.; et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 2009, 199, 936-944. [CrossRef] [PubMed]
33. Brown, D.R.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.E.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Koutsky, L.A.; Tay, E.H.; Garcia, P.; et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 2009, 199, 926-935. [CrossRef] [PubMed]
34. Paavonen, J.; Jenkins, D.; Bosch, F.X.; Naud, P.; Salmeron, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.L.; Kitchener, H.C.; Castellsague, X.; et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369, 2161-2170. [CrossRef]